Teruyuki Sano, PhD

Gut microbiome has been recognized as promotors to increase the anti-tumor immunity during the checkpoint inhibitor treatments. On the other hand, gut microbiome can be highly associated with tissue inflammation including autoimmune and inflammatory diseases. Our goals are to categorize human microbiome to 1) promote anti-tumor immunity and 2) contribute to the treatment-induced immune related adverse events (irAE).